Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Fasting Plasma Trimethylamine-N-Oxide as a Risk Marker of Poor Renal Outcomes, Cardiovascular Disease, and Mortality in Patients with Type 1 Diabetes with Diabetic Nephropathy

Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. ASN Kidney Week 2017

    Activity: Participating in or organising an eventOrganisation of and participation in conference

  1. Essential Branched-Chain Amino Acids and Ribonic Acid Are Associated with Cardiorenal Events in Type 1 Diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment of the Sublingual Microcirculation with the GlycoCheck System: Reproducibility and Examination Conditions

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Hypoxia in individuals with type 1 diabetes and macroalbuminuria is associated with autonomic dysfunction

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations
Background Trimethylamine-N-Oxide (TMAO) is a metabolite of phosphatidylcholine, choline and carnitine produced by the gut microbiota from ingested animal foods. It has been suggested as an independent gut microbiota derived risk factor for renal and cardiovascular disease (CVD). Patients with type 1 diabetes are at increased risk of renal and cardiovascular disease and early mortality. We investigated associations between plasma TMAO and outcomes in a prospective study. Methods TMAO was measured at baseline in 384 patients with type 1 diabetes with diabetic nephropathy (u-AER > 300 mg/g), 61 % were male, mean age was 42 years and eGFR 66 ml/min/1.73m2. Fasting plasma levels of TMAO were measured using stable isotope dilution tandem mass-spectrometry. Endpoints included mean yearly decline in 51Cr EDTA GFR (follow-up (FU) up to 12 years), ESRD (n=65; mean FU: 7.2 years), fatal and non-fatal CVD (n=154; mean FU: 7.5 years) and all-cause mortality (n=134; mean FU: 9.0 years). Associations between TMAO and the endpoints were tested using linear regression or Cox proportional hazard regression in uni- and multivariate analyses adjusting for conventional risk factors at baseline. Results Plasma TMAO was inversely associated with baseline eGFR (R2: 0.42; p<0.001). In univariate analysis higher TMAO was associated with all endpoints (p≤0.002). All endpoints remained significant associated with higher TMAO after adjustment for baseline age, diabetes duration, sex, smoking, systolic blood pressure, cholesterol, HbA1c and u-AER (p ≤ 0.014). After further adjustment for baseline eGFR significance was lost for all endpoints, except for CVD events (HR per doubling: 1.22, [1.05-1.41]; p=0.010). Conclusion In type 1 diabetes patients with diabetic nephropathy, higher fasting plasma TMAO level was predictive of poor renal outcomes, CVD events and mortality independent of conventional risk factors. Only the relation to CVD events remained after further adjustment for baseline eGFR. This elucidated the close relationship between TMAO and renal function.
Original languageEnglish
Article numberSA-OR113
JournalJournal of the American Society of Nephrology
Pages (from-to)102-103
Publication statusPublished - 4 Nov 2017
EventASN Kidney Week 2017 - Ernest N. Morial Convention Center, New Orleans, United States
Duration: 31 Oct 20175 Nov 2017


ConferenceASN Kidney Week 2017
LocationErnest N. Morial Convention Center
CountryUnited States
CityNew Orleans
Internet address


ASN Kidney Week 2017


New Orleans, United States

Event: Conference

ID: 58494595